Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And this - Su, B., Xiao, J., Underhill, P., Deka, R., Zhang, W., Akey, J., Huang, W., Shen, D., Lu, D., Luo, J., Chu, J., Tan, J., Shen, P., Davis, R., Cavalli-Sforza, L., Chakraborty, R., Xiong, M., Du, R., Oefner, P., Chen, Z., Lin, J. (1999) Y chromosome evidence for northward migration of modern humans in East Asia during the last ice age. Am.J.Hum.Genet., 65, 1718-1724.
Tell me the University of Stanford and this guy Underhill is not playing footies with Tony - L. Jin, P. Underhill, V. Doctor, R. W. Davis, P. Shen, L. L. Cavalli-Sforza, and P. Oefner. "Distribution of haplotypes from a chromosome 21 region distinguishes multiple prehistorical human migrations." PNAS, Vol. 96, No. 7, 1999.
How much you want to bet this guy Underhill is helping Dnap.T. M.U. Wagner, K. Hirtenlehner, P. Shen, R. Moeslinger, D. Muhr, E. Fleischmann, H. Concin, W. Doeller, A. Haid, A. H. Lang, P. Mayer, E. Petru, E. Ropp, G. Langbauer, E. Kubista, O. Scheiner, P. Underhill, J. Mountain, M. Stierer, C. Zielinski and P. Oefner. "Global sequence diversity of BRCA2: Analysis of 71 breast cancer families and 95 control individuals of world wide populations." Human Molecular Genetics, Vol. 8, No. 3, 413-23, 1999.
Ming Very nice - Remember Lonnie Bookbinder?
http://www.sema4usa.com/Company/events/LifeSciences2002.htm
Semaphore Dedicates Life Sciences Diligence Practice
Firm emphasizes and expands Technology and Sciences diligence to Bio/Pharma markets.
(Boston- London- Zurich) Sema4, Inc. (Semaphore) announces the expansion of its Technology Diligence practice. Stating that Semaphore clients are experiencing greater activity in the Life Sciences markets, Semaphore CEO Mark S. DiSalvo states “We thought it appropriate to greater emphasize the skills and resources we have to provide assurance and Independent Verification and Validation in the Life Sciences and Bio/Pharma markets, especially since our clients are asking us to perform this level of assurance.”
This dedicated Life Sciences business practice was created to provide visibility and clarity to the decision-making process. “It facilitates informed judgments on risk and opportunity. The Life Sciences are often subject to misunderstanding, misapplication and misrepresentation,” said DiSalvo. DiSalvo explained that this confusion has a deleterious effect on productivity in even the most business savvy environments. Semaphore research has discovered that when Technology Diligence is applied prior to, or in concert with, a funding event it provides appropriate and necessary discipline to the judgment process. The result allows for increased confidence in the decision contemplated and executed. Research confirms that Bio/Pharma projects such as drug development are nearly always over budget, behind schedule, or are abandoned completely. Facts are that the FDA approves less than 2% of the drug pipeline. Those that do receive approval often are not commercially successful. Semaphore services in this space include Clinical Trial review, FDA compliance and certification process monitoring, proof of science concept, and acquisition target validation.
The firm has significantly expanded its resources globally in the Life Sciences space. Richard Gabriel former CEO of Calix Corporation is the point person for the firm as head of Life Sciences diligence services practice. “I am delighted to join the quality team represented by Semaphore. Its skills providing real-world diligence from Emerging Technologies to Enterprise Software to Life Sciences are legendary,” he added. His team includes: Hector Gomez, MD, Ph.D, former CEO of Transcend Therapeutics, Inc. and Lonnie Bookbinder, Ph.D, an experienced large Pharma executive. “The strength of this dedicated team will offer our clients the clearest direction and best assurance of success possible. We bring hard science and business savvy to the table every day,” Gabriel added.
For any new investors, Richard Gabriel is the DNAP CEO/President and Hector Gomez is the DNAP CHasirman and Chief Medical Officer, hence the interest in what Dr. Bookbinder gets up to. We always found it difficult to find out much about Lonnie (leaving aside Lewis & Clark expedition and Ribi Group disgruntled investor related bits and pieces). Here's something I came across today though:
http://66.102.9.104/search?q=cache:_UE3ehBGgqUJ:www.efeckta.com/company.php3+%22lonnie+bookbinder%22....
Lonnie Bookbinder, PhD – Vice President, Marketing
Dr. Bookbinder has over 30 years experience in the biopharmaceutical industry. Lonnie has a BS in Biological Sciences, and has done post-grad work in Pharmacology, Clinical Research, Toxicology, earning an MBA and Ph.D. in Business Management. He has served as Chief Operating Officer, CellPath, a start-up drug discovery company; Vice-President Corporate Development, at Ribi ImmunoChem, a cancer vaccine development company; Vice-President Corporate Development, at Nycomed-Salutar, a drug development company. In addition, he served as Director, OEM agreements at In-Vivo Business Unit, Immunomedics, and key account executive at Lederle Labs.
This is from a cached page for this site, the current page does not have Lonnie suggesting that he is perhaps no longer with the company concerned. It does provide a bit more background though.
Special from Lonnie Bookbinder, PhD, MBA to RIBI shareholders at www.rsvc.org
The author of these observations has a thirty-year career in biopharmaceuticals and worked for RIBI from 1994-1997.
As most are aware, the majority of RIBI sales are derived from MPL and other adjuvants, which are refined as a part of a modified bacteria causing a cascading effect of immune responses. RIBI adjuvants, especially MPL, are considered valuable and useful in many different vaccine candidates.
Importantly, to expand the base of knowledge, RIBI scientists initiated research to develop a synthetic adjuvant and have been successful. They have discovered, synthesized, tested and patented a next generation of super adjuvants. Think of these discoveries as a valuable franchise for the future of immunology. RIBI publications note that RIBI's second generation adjuvant technology platform is based on novel AGP- aminoalkyl glucosamine phosphate- adjuvants. These new synthetic compounds display potent bioactivity, possess an excellent safety profile and are amenable to alternative methods for vaccine delivery, such as intranasal delivery. Synthetic AGP compounds also may prove advantageous in ease of formulation, manufacturing scale-up and simplified quality assurance. In the hands of RIBI scientists, AGP's have been successfully used in pre-clinical testing of tetanus, hepatitis and influenza vaccines. RIBI scientists and managers confirm the worth of the AGP product derivatives and vaccine producers want it. There is a very significant potential value in AGP for RIBI.
This writer believes that RIBI is a treasure trove of potential and actual lines of research and that RIBI stock is worth much more than $2.00 per share. This writer believes that the RIBI Shareholder Value Committee suggestions represent the best way to realize the longterm value of RIBI Shares. Defeat of the Corixa offer is the first step in the right direction. Eighteen years of RIBI employees' scientific research and development deserves to be fully exploited. A sell out merger at $2.00 per share should be unsatisfactory to independent RIBI shareholders.
See my post back on - http://www.investorshub.com/boards/read_msg.asp?message_id=1382399
Special from Lonnie Bookbinder, PhD, MBA to RIBI shareholders at www.rsvc.org
The author of these observations has a thirty-year career in biopharmaceuticals and worked for RIBI from 1994-1997.
As most are aware, the majority of RIBI sales are derived from MPL and other adjuvants, which are refined as a part of a modified bacteria causing a cascading effect of immune responses. RIBI adjuvants, especially MPL, are considered valuable and useful in many different vaccine candidates.
Importantly, to expand the base of knowledge, RIBI scientists initiated research to develop a synthetic adjuvant and have been successful. They have discovered, synthesized, tested and patented a next generation of super adjuvants. Think of these discoveries as a valuable franchise for the future of immunology. RIBI publications note that RIBI's second generation adjuvant technology platform is based on novel AGP- aminoalkyl glucosamine phosphate- adjuvants. These new synthetic compounds display potent bioactivity, possess an excellent safety profile and are amenable to alternative methods for vaccine delivery, such as intranasal delivery. Synthetic AGP compounds also may prove advantageous in ease of formulation, manufacturing scale-up and simplified quality assurance. In the hands of RIBI scientists, AGP's have been successfully used in pre-clinical testing of tetanus, hepatitis and influenza vaccines. RIBI scientists and managers confirm the worth of the AGP product derivatives and vaccine producers want it. There is a very significant potential value in AGP for RIBI.
This writer believes that RIBI is a treasure trove of potential and actual lines of research and that RIBI stock is worth much more than $2.00 per share. This writer believes that the RIBI Shareholder Value Committee suggestions represent the best way to realize the longterm value of RIBI Shares. Defeat of the Corixa offer is the first step in the right direction. Eighteen years of RIBI employees' scientific research and development deserves to be fully exploited. A sell out merger at $2.00 per share should be unsatisfactory to independent RIBI shareholders.
see my post from - http://www.investorshub.com/boards/read_msg.asp?message_id=1252974
to promote partnerships between British Pharmaceutical/Biotech and US/Canadian Pharmacogenomics companies.
DNAPrint to Present as Part of British Consulate Biopartnering Effort
SARASOTA, Fla.--(BUSINESS WIRE)--June 27, 2002--DNAPrint genomics, Inc. (OTCBB:DNAP - News) announced today that the company has been invited by the British Consulate to present at an exclusive gathering for a group of UK pharmaceutical and biotech companies.
The meeting was established by the Trade Partners UK initiative of the British Consulate to promote partnerships between British Pharmaceutical/Biotech and US/Canadian Pharmacogenomics companies. The meeting will take place October 10-11 in Washington D.C.
The United Kingdom (UK) is the current, and historical home for 75% of all European biotechnology companies, including Glaxo Wellcome, SmithKline Beecham (now, GlaxoSmithKline) (NYSE:GSK - News), and Roche (SWX:RO). For more information about the Consulates efforts, please see http://www.itp.org.uk/bio2000.html.
*************************************************************
Now that some time has past since - What do you think.
1USGrant,Thanks and have a nice day i'm taking the kids to the park.
There can be many reasons behind asking questions. And answers and questions can be to totally unrelated elements depending on the goal and mission of the one asking the questions.If your goal is to instill doudt,uncertainty,disbelief,or confusion than asking the right questions is the weapon of choice.Of course the questions will need to be of a certain quality. The easer it is to answer the less likely you will succeed in reaching your goal. The idea is to ask questions that offer the least amount of resistance,that few people can answer. The fewer people can answer, the greater the chance of reaching your goal.Instilling distrust and confussion is the order of the day.Also there are other reasons as well.There's a guy at work who is always criticizing issues. When ever there is a attempt to answer his attacks he walks a way or starts shouting in a loud voice.He's not interested in answers only in appearing to others to know it all,he has a big EGO and needs to feed it.So in these 2 cases you can have both the need to appear to others as BIG and Important {answers as being not important} and the need to reach the Goal of instilling distrust and confusion, to introduce by gradual, persistent efforts, implanting ideas via the right questions into the minds of others.You only need to ask the right questions so that few people can answer and you met your goal. Once you Cause conflict with members of the group then you have reach your goal because now it will run on a power of its own and Bang you won.You Meet your Ego's needs and cause dissension and reached your goals.Stock sold.There's a BIG DIFFERENCE BETWEEN one who asks questions to learn and grow and one who has an AGENDA.Or do you really think we dont know the difference.
House Bill 2703: AN ACT relating to the testing of certain physical evidence, crime laboratory accreditation, and the admissibility of evidence examined or tested by a crime laboratory.
House Bill 2703 has changed the rules on laboratory accreditation.
Below are the links to the Texas Register concerning the Administrative Rules (Emergency and Proposed) dealing with HB 2703. Feel free to share the links with anyone you may have contact with concerning the accreditation process.
The 7 page document is the proposed emergency rules.
http://www.sos.state.tx.us/texreg/archive/August82003/EMERGENCY/37.PUBLIC%20SAFETY%20AND%20CORRECTIO...
The 9 page document is the proposed regular rules.
http://www.sos.state.tx.us/texreg/archive/August82003/PROPOSED/37.PUBLIC%20SAFETY%20AND%20CORRECTION...
Dr, Urbanovsky, with DPS, is in contact with Mike Blinn of the TCEQ Special Investigations Unit. They are trying to reach an accord on how to handle this problem. Mike Blinn believes that we should emphasize that splits are not practical because we would probably be breaking the law in storing them if the material or waste is hazardous. We may also need to address hold times and sample size (some samples are just too small to split such as the "P" trap under a sink when testing on a meth lab). Mike is suggesting that DPS in their rules allow accreditation for private labs if they meet TCEQ's accreditation process.
Dr. Urbanovsky needs to know why environmental labs require different accreditation than regular crime labs. Please look at the above links and make comments to him at the address listed below.
Comments need to be forwarded to
Mr. Ron Urbanovsky
Director, Laboratory Services
Texas Department of Public Safety
Crime Laboratories
P. O. Box 4143
Austin, TX 78765-4143
Tony 's been banging away at this for a while now,whooooooooo
Take a Look - Affymetrix and S.Sinha from Reliagene and my God who is our mystery man Ron Urbanovsky ? http://www.afdaa.org/mminutes5.html
Ann441j, Thanks but all i get is you have to be a member.
Yes this is true BUT how are they marketing Dnap's Product.I dont see it anywhere.
Maybe i missed something but there's nothing on ReliaGene web site about Dnap and or products.A lot of good that will do
Someone bought 100 shares at $5.50
That was not there yesterday, whats going on.
HOLY MEATBALLS $5.50 Sun Citys
SUN CITY INDUSTRIES "ask" just went up to $5.50 on 1 trade whats up !!!!!!
samlion - Here's what Tony had to say about FDA approval. The clinical trial for OVANOME will be finished in early 2004 An application for approval to market, if required, will be submitted to the FDA by mid-2004 and approval obtained by early 2005. DNAP has a patent pending for compositions and methods relating to OVANOME. Sales of the OVANOME products to labs in 2005 will result in income of $4 million. This product launch will create a new, emerging US market of over $16 million. OVANOME is forecast to reach a peak-year sales record of $12 million in year three and hold steady for several years as the classifier test of choice in this market niche.
cosmiclifeform,Thanks for your view.God Bless
Worktoply,I thought one of the requirments for accreditation dor Dnap was you had to have some sort of working relationship with a lab that already had accreditation. Could this mean Dnap is getting close to its own accreditation
Directors, senior management and staff
http://www.hkgem.com/newlistings/prospectuses/e_8031pro-20020522chap16.pdf
More on Dr. Antoine Noujaim -
http://www.pharmacy.ualberta.ca/Noujaim.pdf
AltaRex Announces Lifetime Achievement Award for Founder
EDMONTON, ALBERTA--(CCNMatthews - Jun 1, 2004) - AltaRex Medical
Corp. (TSX: ALT) is pleased to announce that the company's
founder and CEO, Dr. Antoine Noujaim, will receive a lifetime
achievement award from the Canadian Society for Pharmaceutical
Sciences. The award recognizes his outstanding and continuous
contributions in the fields of radiopharmaceutics and
biotechnology. Dr. Noujaim will formally accept the award at a
reception to be held in Vancouver on June 11, 2004.
Dr. Noujaim is a Professor Emeritus of the University of Alberta.
He has been involved in the startup of several biotechnology
companies, is co-founder of Biomira Inc. and founder of ViRexx
Medical Corp. Dr. Noujaim serves on numerous corporate and
scientific advisory boards and is an inventor on over 100 pending
and issued patents.
AltaRex Medical Corp. is focused on the research, development and
commercialization of foreign antibodies that modulate the immune
system for the treatment of certain cancers and other diseases
where there exists an unmet medical need. Additional information
about AltaRex Medical Corp. can be found on its website at
www.altarex.com.
We going to the MOOOOONNNNN $$$$$$
Dr. Antoine (Tony) Noujaim
Director and Past Chairman of the Board
Dr. Noujaim holds a doctorate in bionucleonics from Purdue University. He has been Chairman of the board of AltaRex Inc. (a public biopharmaceutical company listed on the Toronto Stock Exchange “TSE”), from November, 1995 to July 2002. Dr. Noujaim also served as President and Chief Executive Officer of AltaRex Inc. from November, 1995 to February, 1998. From 1999 to present, Dr. Noujaim has been a Director of Oncolytic Biotech Inc., a company currently trading on the TSE. From 1994 to 1999, Dr. Noujaim was a Director of Synsorb Inc., a company trading on NASDAQ and the TSE. Both Oncolytic Biotech Inc. and Synsorb Inc. are Canadian biopharmaceutical companies based in Calgary, Alberta. Prior to the formation of AltaRex Inc., Dr. Noujaim was the President of Biomira Research Inc., a division of Biomira Inc., a public biopharmaceutical company trading on NASDAQ and the TSE, which Dr. Noujaim helped found. From 1985 to 1995, he was Senior Vice President and Chief Operating Officer of the Immunoconjugate Division of Biomira Inc. For the past five years, Dr. Noujaim has been serving as Chairman of the Board and President of Noustar Technologies Inc., a technology venture capital company which is 100% owned by Dr. Noujaim. Dr. Noujaim is also a significant shareholder in and Chairman of the Board of Novolytic Corp., an Edmonton based private biotechnology company dealing with cancer research and development. Dr. Noujaim is formerly the President and currently a director of the Alberta Biotechnology Association and serves on boards of directors of several knowledge-based companies.
Dr. Antoine A. Noujaim is co-inventor with Dr. Tan on the SimBioDas tm platform. Man we going to the moooooooonnnnnnn
Monoclonal Antibodies in the Treatment of Cancer
Dr. Antoine A. Noujaim - http://www.cmius.com/albcancerprog.htm
Alberta Biotechnology Conference - Check out Dr. Antoine Noujaim - http://www.cmius.com/alb%20agenda.htm
Well now I could be wrong BUT I DONT THINK I AM. Everytime i try to do a search on Shaanxi Yangling Daiying Biological Engineering or Yangling Daiying Biological Engineering guess who I keep running into Dr. Tam !!!!!!! and "the Group" and or "Kinetana". Dr. Tam is the founder and inventor along with Dr. Antoine A. Noujaim who is co-inventer, and their team. The Group and Kinetana both have the same people working for them at the same address Hong Kong and Canada.Sun City Industries Enters into Reorganization Agreement with China Based Biotech & Pharmaceutical Company Agreement Signed With Yangling Daiying Biological Engineering Co., Ltd. see Thursday April 22 news release http://biz.yahoo.com/bw/040422/226216_1.html . This is it. Dnap and Kinetana Locked in to each other.See their web. http://www.kinetana.com/
1USGRANT,Thanks for your view. No problem here with your responce on the RB board their mostly animals over there anyway. But got to go for now and again Thanks.
Gcbr,Thanks for your input.I like the idea of Fathwer and son looking out for each other.
Ming. Why would Tony and Father or Dnap buy up {96% of the auth. shares} Sun City Industries and make Tony CEO. It cant be just over the SimBioDas tm Technology because that platform does not belong to Sun its just being use by them. Tony could contact "Kinetana" to set up a contract,easy enough done. There must be some thing more to it.I know they contracted the platform out to work on Drugs for Hepatitis C could that be the only reason.I mean Hepatitis C, why not just contract directley with Kinetana and do the work on finding drugs for Hepatitis at Dnap. There must be something more here,god know i dont always see things as they are but this one has be going all over the place.
Ming. did you know "The Group" goe's under the name "Kinetana" and its both in Canada and Hong kong.http://www.kinetana.com/
Dr. Wicks sure get's around.DNAPrintnordic then with DNAPrintAsiapacific then with DNA Phenomics than with Senecio.
Ming. did you know about Dr. Wicks President and co-founder of Senecio Software Inc as of Feb. this year is working as Chief Technology Officer (CTO} at DNA Phenomics.
Ok Thanks Ming. Take a look at this - http://www.hkgem.com/newlistings/prospectuses/e_8031pro-20020522chap14.pdf